文献速递细胞病理与分子病理

临床试验细胞学:小活检与细针穿刺样本的现场快速评估在临床试验及生物标志物研究中的应用

Clinical trial cytology: Use of on-site evaluation of small biopsy and FNA samples for clinical trials and biomarker research studies.
PubMed 文献 · Cancer Cytopathol · 2018-05-02

匹兹堡大学医学中心建立临床试验研究服务,联合病理科、放射科与内科,对细针穿刺(FNA)和/或空芯针活检(CNB)样本进行现场快速评估(ROSE),以确认肿瘤存在。共评估14项临床试验的79例病例,其中77例(97%)仅用于研究;ROSE与最终样本充分性的一致率为96%至100%。结论认为细胞病理实验室可通过ROSE帮助判断临床试验材料充分性,减少不合格或非代表性材料提交。

要点

  • ROSE用于临床试验FNA/CNB样本,与最终充分性一致率达96%–100%。
  • 79例中77例(97%)仅用于研究,多数(76%)需CNB样本。
  • 细胞病理实验室提供ROSE可减少不合格或非代表性材料提交。

核心结论

  • ROSE可确认临床试验FNA和/或CNB样本中肿瘤存在,与最终样本充分性一致率为96%至100%。
  • 细胞病理实验室提供ROSE有助于判断临床试验材料充分性,减少不合格或非代表性材料提交。

研究设计与样本

  • 单中心研究,匹兹堡大学医学中心建立临床试验研究服务,联合病理科、放射科与内科。
  • 临床试验协调员为需要肿瘤样本的患者组织活检并通知细胞病理与放射团队,进行ROSE。
  • 共纳入14项临床试验的79例病例,ROSE用于确认FNA样本和/或CNB触摸印片中肿瘤充分性。

主要发现

  • 79例中77例(97%)仅用于研究。
  • 53例(67%)来自2008至2009年启动的乳腺癌/卵巢癌研究,26例(33%)来自2011至2014年启动的其他肿瘤研究。
  • 多数(60例;76%)需要CNB样本,其中20%在获取CNB前使用FNA进行针道定位,56%仅评估CNB触摸印片而无前置FNA。
  • ROSE与最终样本充分性的一致率为96%至100%。

关键数值与推荐

  • ROSE与最终样本充分性一致率:96%至100%。
  • 79例中77例(97%)仅用于研究;53例(67%)来自乳腺癌/卵巢癌研究,26例(33%)来自其他肿瘤研究。
  • 60例(76%)需要CNB样本;其中20%使用FNA进行针道定位,56%仅评估CNB触摸印片。

临床怎么用

  • 细胞病理实验室可提供ROSE以判断临床试验材料充分性,减少不合格或非代表性材料提交。
  • 建立临床研究服务可增强沟通并优化癌症患者新型研究标本的处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After increased requests for biopsies for clinical trials and biomarker research, the University of Pittsburgh Medical Center created a clinical trial research service that partnered pathology, radiology, and medicine to facilitate rapid on-site evaluation (ROSE) of fine-needle aspiration (FNA) and/or core needle biopsy (CNB) samples to confirm the presence of tumor in these studies. METHODS: Clinical trial coordinators organized biopsies for patients needing tumor samples for trials, and informed the cytopathology and radiology team. ROSE was performed to confirm the presence of sufficient tumor in FNA specimens and/or touch preparations of CNB. RESULTS: A total of 79 cases from a total of 14 clinical trials were evaluated with ROSE, 77 of which (97%) were for research only. There were 53 cases (67%) from breast/ovarian cancer studies that were initiated between 2008 and 2009, whereas 26 cases (33%) included a variety of other tumors for studies that were started between 2011 and 2014. The majority required CNB samples (60 cases; 76%), 20% of which used an FNA for needle placement before obtaining CNB material and 56% of which had touch preparations of the CNB evaluated without a preceding FNA. The concordance rate for ROSE with final adequacy of the sample was 96% to 100%. CONCLUSIONS: The study institution has experienced an increase in the number of clinical trial studies requesting ROSE to confirm the presence of tumor in a variety of malignancies. Cytology laboratories can help with patient care by offering ROSE to determine the adequacy of clinical trial material to minimize the submission of unsatisfactory or nonrepresentative material. Developing a clinical research service enhances communication and the processing of novel research specimens for cancer patients. Cancer Cytopathol 2018. © 2018 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Manzo JL, Cuda J, Pantanowitz L, et al. Clinical trial cytology: Use of on-site evaluation of small biopsy and FNA samples for clinical trials and biomarker research studies. Cancer Cytopathol. 2018. PMID: 29719135. doi:10.1002/cncy.22001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。